Recent findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neoplastic cells. Besides adding CDK7 to the expanding list of cell cycle proteins that impinge on immune regulation, these results support the value of aggravating genomic instability in cancer cells to enable immunological disease control.
Cancer Immunotherapy with CDK7 Inhibitors / Petroni, Giulia; Galluzzi, Lorenzo. - In: TRENDS IN CANCER. - ISSN 2405-8025. - ELETTRONICO. - 6:(2020), pp. 361-363. [10.1016/j.trecan.2020.02.005]
Cancer Immunotherapy with CDK7 Inhibitors
Petroni, Giulia;Galluzzi, Lorenzo
2020
Abstract
Recent findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neoplastic cells. Besides adding CDK7 to the expanding list of cell cycle proteins that impinge on immune regulation, these results support the value of aggravating genomic instability in cancer cells to enable immunological disease control.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
